156 related articles for article (PubMed ID: 35000876)
21. Response to first-line chemotherapy regimen is associated with efficacy of ımmune checkpoint blockade therapies in patients with metastatic urothelial carcinoma.
Tural D; Selçukbiricik F; Ölmez ÖF; Sümbül AT; Erman M; Coşkun HŞ; Artaç M; Kılıçkap S
Int J Clin Oncol; 2022 Mar; 27(3):585-591. PubMed ID: 34762201
[TBL] [Abstract][Full Text] [Related]
22. Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer.
Gómez de Liaño Lista A; van Dijk N; de Velasco Oria de Rueda G; Necchi A; Lavaud P; Morales-Barrera R; Alonso Gordoa T; Maroto P; Ravaud A; Durán I; Szabados B; Castellano D; Giannatempo P; Loriot Y; Carles J; Anguera Palacios G; Lefort F; Raggi D; Gross Goupil M; Powles T; Van der Heijden MS
Eur Urol; 2020 Feb; 77(2):269-276. PubMed ID: 31699525
[TBL] [Abstract][Full Text] [Related]
23. New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors.
Bamias A; Merseburger A; Loriot Y; James N; Choy E; Castellano D; Lopez-Rios F; Calabrò F; Kramer M; de Velasco G; Zakopoulou R; Tzannis K; Sternberg CN
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36627145
[TBL] [Abstract][Full Text] [Related]
24. Clinical variables associated with immune checkpoint inhibitor outcomes in patients with metastatic urothelial carcinoma: a multicentre retrospective cohort study.
Labidi S; Meti N; Barua R; Li M; Riromar J; Jiang DM; Fallah-Rad N; Sridhar SS; Del Rincon SV; Pezo RC; Ferrario C; Cheng S; Sacher AG; Rose AAN
BMJ Open; 2024 Mar; 14(3):e081480. PubMed ID: 38553056
[TBL] [Abstract][Full Text] [Related]
25. Organ-specific efficacy in advanced non-small cell lung cancer patients treated with first-line single-agent immune checkpoint inhibitors.
Deng J; Gao M; Gou Q; Xu C; Yan H; Yang M; Li J; Yang X; Wei X; Zhou Q
Chin Med J (Engl); 2022 Jun; 135(12):1404-1413. PubMed ID: 35869859
[TBL] [Abstract][Full Text] [Related]
26. Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis.
Rizzo A; Mollica V; Massari F
Eur Urol Focus; 2022 Jan; 8(1):152-159. PubMed ID: 33516645
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Factors in Patients with Metastatic Breast Cancer with Bone-Only Metastases.
Parkes A; Warneke CL; Clifton K; Al-Awadhi A; Oke O; Pestana RC; Alhalabi O; Litton JK; Hortobagyi GN
Oncologist; 2018 Nov; 23(11):1282-1288. PubMed ID: 30120166
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of immune-checkpoint inhibitors in PD-L1 selected or unselected patients vs. control group in patients with advanced or metastatic urothelial carcinoma.
Guo L; Wang X; Wang S; Hua L; Song N; Hu B; Tong Z
Oncoimmunology; 2021 Mar; 10(1):1887551. PubMed ID: 33747636
[TBL] [Abstract][Full Text] [Related]
29. Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population.
Necchi A; Pond GR; Pal SK; Agarwal N; Bowles DW; Plimack ER; Yu EY; Ladoire S; Baniel J; Crabb S; Niegisch G; Srinivas S; Berthold DR; Rosenberg JE; Powles T; Bamias A; Harshman LC; Bellmunt J; Galsky MD;
Clin Genitourin Cancer; 2018 Apr; 16(2):e483-e490. PubMed ID: 29158079
[TBL] [Abstract][Full Text] [Related]
30. The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy.
Alqaisi HA; Stecca C; Veitch ZW; Riromar J; Kaiser J; Fallah-Rad N; Jiang DM; North S; Samnani S; Alimohamed N; Sridhar SS
Ther Adv Med Oncol; 2022; 14():17588359221094879. PubMed ID: 35520101
[TBL] [Abstract][Full Text] [Related]
31. The impact of body mass index on survival endpoints among patients with metastatic urothelial carcinoma undergoing treatment with immune checkpoint inhibitors: A real-world multicenter analysis.
Huang SY; Su PJ; Lin CT; Kuo MC; Chen YH; Wu CC; Luo HL; Chen CH; Chou CC; Huang CC; Kuo CW; Su YL
Cancer Med; 2024 Jan; 13(2):e7008. PubMed ID: 38334504
[TBL] [Abstract][Full Text] [Related]
32. Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bongiovanni A; Foca F; Menis J; Stucci SL; Artioli F; Guadalupi V; Forcignanò MR; Fantini M; Recine F; Mercatali L; Spadazzi C; Burgio MA; Fausti V; Miserocchi A; Ibrahim T
Front Immunol; 2021; 12():697298. PubMed ID: 34858389
[TBL] [Abstract][Full Text] [Related]
33. [The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].
Ma SX; Ma N; Han J; He Z; Wang L; Wang Q
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):922-929. PubMed ID: 35385963
[No Abstract] [Full Text] [Related]
34. Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma.
Meynard L; Dinart D; Delaunay B; Fléchon A; Saldana C; Lefort F; Gravis G; Thiery-Vuillemin A; Cancel M; Coquan E; Ladoire S; Maillet D; Rolland F; Boughalem E; Martin S; Laramas M; Crouzet L; Abbar B; Falkowski S; Pouessel D; Roubaud G
Eur J Cancer; 2022 Nov; 175():43-53. PubMed ID: 36088671
[TBL] [Abstract][Full Text] [Related]
35. Bone metastasis attenuates efficacy of immune checkpoint inhibitors and displays "cold" immune characteristics in Non-small cell lung cancer.
Zhu YJ; Chang XS; Zhou R; Chen YD; Ma HC; Xiao ZZ; Qu X; Liu YH; Liu LR; Li Y; Yu YY; Zhang HB
Lung Cancer; 2022 Apr; 166():189-196. PubMed ID: 35306320
[TBL] [Abstract][Full Text] [Related]
36. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
[TBL] [Abstract][Full Text] [Related]
37. Prognostic impact of radiological tumor burden in patients with metastatic urothelial carcinoma treated with pembrolizumab.
Katayama S; Iwata T; Kawada T; Okamoto Y; Sano Y; Kawago Y; Miyake S; Moriwake T; Kuinose A; Horikawa Y; Tsuboi K; Tsuboi I; Sakaeda K; Nakatsuka H; Takamoto A; Hirata T; Shirasaki Y; Yamasaki T; Morinaka H; Nagasaki N; Hara T; Ochi A; Okumura M; Watanabe T; Sekito T; Kawano K; Horii S; Yamanoi T; Nagao K; Yoshinaga K; Maruyama Y; Tominaga Y; Sadahira T; Nishimura S; Edamura K; Kobayashi T; Kusumi N; Kurose K; Yamamoto Y; Sugimoto M; Nakada T; Sasaki K; Takenaka T; Ebara S; Miyaji Y; Wada K; Kobayashi Y; Araki M
Urol Oncol; 2024 Mar; 42(3):70.e11-70.e18. PubMed ID: 38129282
[TBL] [Abstract][Full Text] [Related]
38. Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
Brown JT; Liu Y; Shabto JM; Martini D; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni L; Joshi SS; Kissick H; Ogan K; Nazha B; Carthon BC; Kucuk O; Harris WB; Master VA; Bilen MA
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326170
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the clinicopathological characteristics and prognosis between Chinese patients with breast cancer with bone-only and non-bone-only metastasis.
Zhang L; Zhang J; Li Z; Wu Y; Tong Z
Oncol Lett; 2020 Oct; 20(4):92. PubMed ID: 32831911
[TBL] [Abstract][Full Text] [Related]
40. Interim fluorine-18 fluorodeoxyglucose positron emission tomography for early metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma.
Giannatempo P; Alessi A; Miceli R; Raggi D; Farè E; Nicolai N; Serafini G; Padovano B; Piva L; Biasoni D; Torelli T; Catanzaro M; Stagni S; Maffezzini M; Mariani L; Gianni AM; Sonpavde G; Salvioni R; Necchi A; Crippa F
Clin Genitourin Cancer; 2014 Dec; 12(6):433-9. PubMed ID: 24787972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
